Latest Mesoblast News & Updates

See the latest news and media coverage for Mesoblast. We track all announcements, press releases, and industry mentions in real time, all in one place.

Mesoblast

Commercial-stage biotechnology company developing allogeneic cell therapies

mesoblast.com

Headquarters: Melbourne, Australia
Founded year: 2004
Company type: Public company
Number of employees: 120–200
Industry: Biotechnology & Medical Research

Last updated October 29

Latest news about Mesoblast

In short: Mesoblast reported Ryoncil revenue growth and narrowed losses, advancing its Phase 3 back pain trial and pipeline.

Company announcements

October 29 Mesoblast

Mesoblast reports Q1 revenue growth and operational improvements

Net revenues rose 44% to $28 million. The company completed its Phase 3 trial for chronic low back pain and secured FDA alignment on filing.

October 28 Mesoblast

Mesoblast files quarterly activities and cash flow report

The filing covers financial performance for the period ended October 29, 2026. Share price was 2.28 AUD as of that date.

October 15 Mesoblast

Mesoblast reports increased revenue and improved operating spend

The company announced these financial results in an October 16, 2026 news release.

October 12 Mesoblast

Mesoblast releases its annual report to shareholders

The document is available as a PDF download from the investor media center dated October 12, 2026.

Media coverage

October 15 Capital Brief

Mesoblast shares surge as Q1 Ryoncil revenue jumps

Shares in Mesoblast rallied in afternoon trade after the biotech reported higher first quarter earnings compared to the ...

October 7 The Globe and Mail

Mesoblast Posts First Full-Year Ryoncil Revenue Surge and Files 2026 Annual Report

Detailed price information for Mesoblast Ltd ADR (MESO-Q) from The Globe and Mail including charting and trades.

September 23 Zone Bourse

Mesoblast receives US FDA approval for a new power trial

Mesoblast has received approval from the US Food and Drug Administration to conduct a new power trial, the T-cell Proliferation Inhibition BioAssay...

September 23 Marketscreener

27.08. Mesoblast reduces loss in fiscal year 2026; revenue increases MT

Mesoblast Limited: Price, Charts, Quotes, Recommendations, Fundamental Data, Real-time News and Analysis Stock Mesobblast Limited | A0DNPW | AU000000MSB8 | Australian S.E.

Never miss news about Mesoblast

Track Mesoblast and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Mesoblast competitors & trending companies

Browse news for competitors to Mesoblast and other trending companies.